KRMD
Neutral signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Unavailable or mixed. Current ratio 2.44 · operating margin -7.2% — readings disagree
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
ACHAT TOTAL: 32000 titres (~101120 USD)
- Insiders
- KALBERMATTEN ADAM R
- Total bought
-
$101,120
Avg buy (VWAP, 90d window) $3.16 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
- Last activity
- 2026-09-08
- Last synced
-
2026-09-10 10:26:50
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-08 | KALBERMATTEN ADAM R | Buy | 32,000 | $3.16 | $101,120 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Neutral signalScored 2026-09-10
KRMD shows encouraging operational progress with a rare EPS beat and 18% revenue growth, supported by a meaningful insider purchase post-earnings that signals some internal conviction.
The first sentence of the analysis written for KRMD on 2026-09-10 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 62.3% | 63.4% | 58.6% | 55.1% | 58.6% | |
| Ebit Margin | -6.4% | -18.0% | -34.3% | -38.3% | -27.1% | |
| Ebitda Margin | -4.4% | -15.7% | -31.2% | -36.2% | -25.1% | |
| Operating Profit Margin | -7.2% | -19.2% | -36.0% | -38.6% | -29.9% | |
| Pretax Profit Margin | -6.4% | -18.0% | -34.3% | -38.3% | -27.1% | |
| Continuous Operations Profit Margin | -6.4% | -18.0% | -48.2% | -31.0% | -19.4% | |
| Net Profit Margin | -6.4% | -18.0% | -48.2% | -31.0% | -19.4% | |
| Bottom Line Profit Margin | -6.4% | -18.0% | -48.2% | -31.0% | -19.4% | |
| Current Ratio | 2.439 | 2.657 | 4.548 | 4.282 | 7.788 | |
| Quick Ratio | 1.990 | 2.267 | 3.766 | 3.362 | 6.514 | |
| Solvency Ratio | -0.164 | -0.509 | -1.588 | -0.734 | -0.856 | |
| Cash Ratio | 1.083 | 1.330 | 2.578 | 2.502 | 5.287 | |
| Price To Earnings Ratio | -101.751 | -29.615 | -8.200 | -18.789 | -30.000 | |
| Price To Earnings Growth Ratio | 1.814 | 0.523 | -0.142 | -0.209 | -0.122 | |
| Forward Price To Earnings Growth Ratio | 1.814 | 0.523 | -0.142 | -0.209 | -0.122 | |
| Price To Earnings Diluted Ratio | -101.751 | -29.615 | -8.200 | -18.789 | -30.000 | |
| Price To Earnings Diluted Growth Ratio | 1.814 | 0.523 | -0.142 | -0.209 | -0.122 | |
| Price To Book Ratio | 15.741 | 10.488 | 5.511 | 5.129 | 3.648 | |
| Price To Sales Ratio | 6.525 | 5.241 | 3.934 | 5.759 | 5.669 | |
| Price To Free Cash Flow Ratio | -570.815 | -109.045 | -19.656 | -19.578 | -28.363 | |
| Price To Operating Cash Flow Ratio | 580.329 | -551.553 | -22.929 | -29.726 | -30.826 | |
| Debt To Assets Ratio | 0.124 | 0.147 | 0.156 | 0.116 | 0.015 | |
| Debt To Equity Ratio | 0.205 | 0.237 | 0.218 | 0.157 | 0.017 | |
| Debt To Capital Ratio | 0.170 | 0.192 | 0.179 | 0.136 | 0.016 | |
| Long Term Debt To Capital Ratio | 0.148 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.654 | 1.619 | 1.398 | 1.351 | 1.131 | |
| Working Capital Turnover Ratio | 3.467 | 2.427 | 1.476 | 1.008 | 0.708 | |
| Operating Cash Flow Ratio | 0.056 | -0.044 | -1.098 | -0.777 | -0.901 | |
| Operating Cash Flow Sales Ratio | 0.011 | -0.010 | -0.172 | -0.194 | -0.184 | |
| Free Cash Flow Operating Cash Flow Ratio | -1.017 | 5.058 | 1.166 | 1.518 | 1.087 | |
| Debt Service Coverage Ratio | -3.394 | -19.523 | -40.945 | -18.634 | -8.061 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.859 | -1.179 | -15.564 | -12.473 | -8.493 | |
| Operating Cash Flow Coverage Ratio | 0.132 | -0.080 | -1.101 | -1.097 | -7.150 | |
| Capital Expenditure Coverage Ratio | 0.496 | -0.246 | -6.006 | -1.929 | -11.512 | |
| Dividend Paid And Capex Coverage Ratio | 0.496 | -0.246 | -6.006 | -1.929 | -11.512 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -145.647 | -32.273 | -11.809 | -14.688 | -18.373 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 62.3% | ▼-1.1% | ▲2.7% |
| Ebit Margin | -6.4% | ▲11.7% | ▲18.4% |
| Ebitda Margin | -4.4% | ▲11.3% | ▲18.1% |
| Operating Profit Margin | -7.2% | ▲11.9% | ▲19.0% |
| Pretax Profit Margin | -6.4% | ▲11.7% | ▲18.4% |
| Continuous Operations Profit Margin | -6.4% | ▲11.6% | ▲18.2% |
| Net Profit Margin | -6.4% | ▲11.6% | ▲18.2% |
| Bottom Line Profit Margin | -6.4% | ▲11.6% | ▲18.2% |
| Current Ratio | 2.439 | ▼-0.217 | ▼-1.903 |
| Quick Ratio | 1.990 | ▼-0.277 | ▼-1.589 |
| Solvency Ratio | -0.164 | ▲0.345 | ▲0.606 |
| Cash Ratio | 1.083 | ▼-0.248 | ▼-1.473 |
| Price To Earnings Ratio | -101.751 | ▼-72.136 | ▼-64.080 |
| Price To Earnings Growth Ratio | 1.815 | ▲1.292 | ▲1.442 |
| Forward Price To Earnings Growth Ratio | 1.815 | ▲1.292 | ▲1.442 |
| Price To Earnings Diluted Ratio | -101.751 | ▼-72.136 | ▼-64.080 |
| Price To Earnings Diluted Growth Ratio | 1.815 | ▲1.292 | ▲1.442 |
| Price To Book Ratio | 15.741 | ▲5.253 | ▲7.637 |
| Price To Sales Ratio | 6.525 | ▲1.284 | ▲1.099 |
| Price To Free Cash Flow Ratio | -570.815 | ▼-461.770 | ▼-421.324 |
| Price To Operating Cash Flow Ratio | 580.329 | ▲1131.882 | ▲591.270 |
| Debt To Assets Ratio | 0.124 | ▼-0.023 | ▲0.012 |
| Debt To Equity Ratio | 0.205 | ▼-0.032 | ▲0.038 |
| Debt To Capital Ratio | 0.170 | ▼-0.022 | ▲0.032 |
| Long Term Debt To Capital Ratio | 0.148 | ▲0.148 | ▲0.118 |
| Financial Leverage Ratio | 1.654 | ▲0.035 | ▲0.223 |
| Working Capital Turnover Ratio | 3.467 | ▲1.040 | ▲1.650 |
| Operating Cash Flow Ratio | 0.056 | ▲0.101 | ▲0.609 |
| Operating Cash Flow Sales Ratio | 0.011 | ▲0.021 | ▲0.121 |
| Free Cash Flow Operating Cash Flow Ratio | -1.017 | ▼-6.075 | ▼-2.579 |
| Debt Service Coverage Ratio | -3.394 | ▲16.129 | ▲14.717 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.859 | ▲2.038 | ▲8.229 |
| Operating Cash Flow Coverage Ratio | 0.132 | ▲0.212 | ▲1.991 |
| Capital Expenditure Coverage Ratio | 0.496 | ▲0.742 | ▲4.335 |
| Dividend Paid And Capex Coverage Ratio | 0.496 | ▲0.742 | ▲4.335 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -145.647 | ▼-113.374 | ▼-101.089 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $268.3M | $176.3M | $112.2M | $160.7M | $133.2M | |
| Enterprise value | $263.0M | $170.8M | $105.1M | $148.2M | $108.4M | |
| EV / Sales | 6.39x | 5.08x | 3.69x | 5.31x | 4.62x | |
| EV / Op. cash flow | 568.70x | -534.07x | -21.49x | -27.42x | -25.10x | |
| EV / Free cash flow | -559.38x | -105.59x | -18.42x | -18.06x | -23.09x | |
| EV / EBITDA | -145.65x | -32.27x | -11.81x | -14.69x | -18.37x | |
| Net debt / EBITDA | 2.98x | 1.06x | 0.79x | 1.24x | 4.19x | |
| Current ratio | 2.44x | 2.66x | 4.55x | 4.28x | 7.79x | |
| Income quality | -0.17x | 0.05x | 0.36x | 0.62x | 0.95x | |
| Graham net-net | $0 | $0 | $0 | $0 | $1 | |
| Tax burden | 100.8% | 100.0% | 140.6% | 81.1% | 71.7% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $11.8M | $11.9M | $15.8M | $22.8M | $32.5M | |
| Invested capital | $19.9M | $19.9M | $23.9M | $31.3M | $34.5M | |
| Return on assets | -9.4% | -22.3% | -48.3% | -20.5% | -11.0% | |
| Operating ROA | -10.7% | -23.2% | -29.0% | -25.8% | -17.3% | |
| Return on tangible assets | -9.6% | -22.9% | -49.6% | -20.8% | -11.3% | |
| Return on equity | -15.5% | -36.1% | -67.5% | -27.6% | -12.5% | |
| Return on invested capital | -14.5% | -31.0% | -41.4% | -24.1% | -13.6% | |
| Return on capital employed | -14.9% | -32.2% | -42.8% | -30.5% | -19.3% | |
| Earnings yield | -1.0% | -3.4% | -12.2% | -5.4% | -3.4% | |
| Free cash flow yield | -0.2% | -0.9% | -5.1% | -5.1% | -3.5% | |
| Capex / Op. cash flow | 201.7% | -405.8% | -16.6% | -51.8% | -8.7% | |
| Capex / Depreciation | 115.1% | 146.0% | 93.6% | 477.2% | 81.0% | |
| Capex / Sales | 2.3% | 3.9% | 2.9% | 10.0% | 1.6% | |
| SG&A / Sales | 56.8% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 10.7% | 15.6% | 20.1% | 17.8% | 10.5% | |
| Stock comp / Sales | 6.6% | 7.8% | 9.7% | 11.0% | 11.5% | |
| Intangibles / Total assets | 2.4% | 2.7% | 2.7% | 1.9% | 2.0% | |
| Days sales outstanding | 58d | 65d | 52d | 47d | 56d | |
| Days payables outstanding | 53d | 49d | 30d | 70d | 46d | |
| Operating cycle | 144d | 148d | 159d | 233d | 285d | |
| Cash conversion cycle | 91d | 99d | 129d | 163d | 239d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+52.2%EV / Sales ▲+26.0%EV / EBITDA ▼-351.3%EV / Op. cash flow ▲+1102.769Earnings yield ▲+0.025
Profitability
Return on equity ▲+0.206Return on assets ▲+0.129Return on invested capital ▲+0.165Return on capital employed ▲+0.173Operating ROA ▲+0.124Income quality ▼-0.228Tax burden ▲+0.008
Efficiency
Days sales outstanding ▼-7.114Days payables outstanding ▲+4.411Operating cycle ▼-3.730Cash conversion cycle ▼-8.141Capex / Sales ▼-0.016R&D / Sales ▼-0.050
Balance-sheet strength
Current ratio ▼-0.217Net debt / EBITDA ▲+1.921Working capital ▼-136158.000Invested capital ▼-10874.000Intangibles / Total assets ▼-0.003
Change over 5 years
Valuation
Market cap ▲+101.5%EV / Sales ▲+38.5%EV / EBITDA ▼-692.7%EV / Op. cash flow ▲+593.804Earnings yield ▲+0.024
Profitability
Return on equity ▼-0.030Return on assets ▲+0.017Return on invested capital ▼-0.009Return on capital employed ▲+0.044Operating ROA ▲+0.066Income quality ▼-1.122Tax burden ▲+0.291
Efficiency
Days sales outstanding ▲+2.124Days payables outstanding ▲+7.222Operating cycle ▼-140.679Cash conversion cycle ▼-147.902Capex / Sales ▲+0.007R&D / Sales ▲+0.001
Balance-sheet strength
Current ratio ▼-5.349Net debt / EBITDA ▼-1.213Working capital ▼-20734746.000Invested capital ▼-14633138.000Intangibles / Total assets ▲+0.005
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-08-06 KORU Medical Systems, Inc. (KRMD) Q2 2026 Earnings Call Transcript KORU Medical Systems, Inc. (KRMD) Q2 2026 Earnings Call Transcript
- 2026-08-05 KORU Medical Systems Q2 Earnings Call Highlights KORU Medical Systems NASDAQ: KRMD reported second-quarter revenue of $12 million, up 18% from a year earlier, as domestic patient starts, market-share gains and international demand supported growth. The company also said it achieved positive net income for the first time since 2019 and raised its full-year gross-margin outlook, while narrowing revenue guidance because certain international prefilled-syringe market launches are taking longer to develop than expected.
- 2026-08-05 KORU Medical Systems, Inc. (KRMD) Q2 Earnings and Revenues Beat Estimates KORU Medical Systems, Inc. (KRMD) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to break-even earnings per share a year ago.
- 2026-08-05 KORU Medical Systems Announces Second Quarter 2026 Results and Updates Full Year 2026 Guidance MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2026. The Company also updated guidance for the full year 2026. Second Quarter 2026 and Recent Highlights Net revenues grew 18% over the p.
- 2026-07-29 KORU Medical Systems to Participate in the Canaccord Genuity 46th Annual Growth Conference MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will participate in the Canaccord Genuity 46th Annual Growth Conference on August 12th, 2026. KORU Medical''s management is scheduled to present at the Canaccord Genuity 46th Annual.
- 2026-07-22 Kaskela Law LLC Announces Investigation of KORU Medical Systems, Inc. (KRMD) and Encourages Long-Term KRMD Shareholders to Contact the Firm PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law is investigating KORU Medical Systems, Inc. (Nasdaq: KRMD) (“KORU”) on behalf of the company''s current shareholders.The investigation seeks to determine whether KORU and/or the company''s officers and directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.KORU shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional information abo.
- 2026-07-15 KORU Medical Systems to Report Second Quarter 2026 Financial Results on August 5, 2026 MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report second quarter 2026 financial results on Wednesday, August 5, 2026. KORU Medical''s management will host a conference call and webcast at 4:30 p.m. ET that day to discus.